These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7913236)

  • 1. Latency increase of auditory-evoked potential component N1 predicts poor neuroleptic response in schizophrenic patients.
    Adler G; Markert U; Gattaz WF
    Pharmacopsychiatry; 1994 Mar; 27(2):68-9. PubMed ID: 7913236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
    Stefánsson SB; Jónsdóttir TJ
    Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
    Schlör KH; Moises HW; Haas S; Rieger H
    Pharmacopsychiatry; 1985 Sep; 18(5):293-6. PubMed ID: 4048264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between residual symptomatology and auditory evoked potentials in schizophrenic outpatients.
    Hegerl U; Gaebel W; Ulrich G
    Pharmacopsychiatry; 1988 Nov; 21(6):329-30. PubMed ID: 2907638
    [No Abstract]   [Full Text] [Related]  

  • 5. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
    Asato N; Hirayasu Y; Hiramatsu K; Ohta H
    Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auditory evoked potentials in schizophrenic patients before and during neuroleptic treatment. Relationship to psychopathological state.
    Adler G; Gattaz WF
    Eur Arch Psychiatry Clin Neurosci; 1993; 242(6):357-61. PubMed ID: 8323986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
    Kathmann N; Wagner M; Rendtorff N; Engel RR
    Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical response to sleep deprivation and auditory-evoked potentials--preliminary results.
    Danos P; Kasper S; Scholl HP; Kaiser J; Ruhrmann S; Höflich G; Möller HJ
    Pharmacopsychiatry; 1994 Mar; 27(2):70-1. PubMed ID: 8029315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment.
    Hirayasu Y; Asato N; Ohta H; Hokama H; Arakaki H; Ogura C
    Biol Psychiatry; 1998 Feb; 43(4):244-53. PubMed ID: 9513733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
    Moxon KA; Gerhardt GA; Adler LE
    Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia.
    Wang J; Hirayasu Y; Hokama H; Tanaka S; Kondo T; Zhang M; Xiao Z
    Psychiatry Clin Neurosci; 2005 Apr; 59(2):209-14. PubMed ID: 15823170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Negative schizophrenic symptomatology and the P 300 potential].
    Drouet A; Hort-Legrand C; Féline A; Métral S
    Encephale; 1993; 19(3):229-35. PubMed ID: 8275908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced auditory evoked potential component N100 in schizophrenia--a critical review.
    Rosburg T; Boutros NN; Ford JM
    Psychiatry Res; 2008 Dec; 161(3):259-74. PubMed ID: 18926573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
    Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
    Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
    Lombertie ER; Durelle G; Fuseau A
    Ann Med Psychol (Paris); 1995 Oct; 153(8):531-4. PubMed ID: 8561400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients.
    Freedman R; Adler LE; Waldo MC; Pachtman E; Franks RD
    Biol Psychiatry; 1983 May; 18(5):537-51. PubMed ID: 6134559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients.
    Nedopil N; Pflieger R; Rüther E
    Pharmacopsychiatria; 1983 Nov; 16(6):201-5. PubMed ID: 6141576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.